Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ARDELYX, INC. | Director | Common Stock | 251K | $1.67M | $6.65 | Jun 14, 2024 | Direct |
Ocuphire Pharma, Inc. | Director | Common Stock | 239K | $422K | $1.77 | Jun 11, 2024 | Direct |
NOVAVAX INC | Director | Stock Option (Right to Buy) | 15.6K | $248K | $15.86 | Jun 12, 2024 | Direct |
NOVAVAX INC | Director | Common Stock | 10.5K | $146K | $13.90 | Jun 12, 2024 | Direct |
NOVAVAX INC | Director | Restricted Stock Units | 10.4K | $145K | $13.90 | Jun 12, 2024 | Direct |
ARDELYX, INC. | Director | Stock Option (Right to Buy) | 40.2K | $93.4K | $2.32 | Jun 14, 2024 | Direct |
Ocuphire Pharma, Inc. | Director | Stock Option (Right to Buy) | 35.2K | Jun 11, 2024 | Direct | ||
Sagimet Biosciences Inc. | Director | Stock Option (Right to Buy) | 23.8K | Jul 18, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ARDX | ARDELYX, INC. | Jun 14, 2024 | 2 | $0 | 4 | Jun 17, 2024 | Director |
NVAX | NOVAVAX INC | Jun 12, 2024 | 4 | $248K | 4 | Jun 14, 2024 | Director |
OCUP | Ocuphire Pharma, Inc. | Jun 11, 2024 | 2 | $0 | 4 | Jun 13, 2024 | Director |
OCUP | Ocuphire Pharma, Inc. | Jan 1, 2024 | 1 | $0 | 4 | Jan 3, 2024 | Director |
OCUP | Ocuphire Pharma, Inc. | Nov 1, 2023 | 1 | $0 | 4 | Nov 13, 2023 | Director |
NVAX | NOVAVAX INC | Oct 29, 2023 | 2 | $0 | 4 | Oct 31, 2023 | Director |
SGMT | Sagimet Biosciences Inc. | Jul 18, 2023 | 6 | $0 | 4 | Jul 20, 2023 | Director |
SGMT | Sagimet Biosciences Inc. | Jul 13, 2023 | 0 | $0 | 3 | Jul 13, 2023 | Director |
ARDX | ARDELYX, INC. | Jun 15, 2023 | 2 | $0 | 4 | Jun 16, 2023 | Director |
NVAX | NOVAVAX INC | Jun 12, 2023 | 2 | $0 | 4 | Jun 13, 2023 | Director |
OCUP | Ocuphire Pharma, Inc. | Apr 19, 2023 | 1 | $0 | 4 | Apr 21, 2023 | Interim CEO and President, Director |
OCUP | Ocuphire Pharma, Inc. | Jan 11, 2023 | 1 | $0 | 4 | Jan 12, 2023 | Director |
NVAX | NOVAVAX INC | Oct 29, 2022 | 2 | $0 | 4 | Nov 1, 2022 | Director |
NVAX | NOVAVAX INC | Oct 29, 2022 | 0 | $0 | 3 | Nov 1, 2022 | Director |
OCUP | Ocuphire Pharma, Inc. | Oct 3, 2022 | 2 | $0.32 | 4 | Oct 4, 2022 | Director |
OCUP | Ocuphire Pharma, Inc. | Jul 1, 2022 | 2 | $0 | 4 | Jul 6, 2022 | Director |
ARDX | ARDELYX, INC. | Jun 15, 2022 | 2 | $0 | 4 | Jun 17, 2022 | Director |
OCUP | Ocuphire Pharma, Inc. | Jun 13, 2022 | 1 | $0 | 4 | Jun 15, 2022 | Director |
OCUP | Ocuphire Pharma, Inc. | Apr 1, 2022 | 1 | $0 | 4 | Apr 5, 2022 | Director |
OCUP | Ocuphire Pharma, Inc. | Jan 3, 2022 | 1 | $0 | 4 | Jan 5, 2022 | Director |
OCUP | Ocuphire Pharma, Inc. | Oct 1, 2021 | 1 | $0 | 4 | Oct 4, 2021 | Director |
OCUP | Ocuphire Pharma, Inc. | Jul 1, 2021 | 1 | $0 | 4 | Jul 2, 2021 | Director |
ARDX | ARDELYX, INC. | Jun 16, 2021 | 2 | $0 | 4 | Jun 21, 2021 | Director |
OCUP | Ocuphire Pharma, Inc. | Jun 7, 2021 | 1 | $0 | 4 | Jun 9, 2021 | Director |